EyePoint Pharmaceuticals Investor Day to Highlight EYP-1901

- Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD announced at ASRS 2022...

Related Keywords

United States ,Watertown ,Massachusetts ,Texas ,American ,George Elston ,Charlesc Wykoff ,Charles Wykoff ,Carld Regillo ,Amy Phillips ,Jay Duker ,Carl Regillo ,Christina Tartaglia ,Dario Paggiarino ,Equinox Sciences ,American Society Of Retinal Surgeons ,Thomas Jefferson University ,Nasdaq ,Eyepoint Pharmaceuticals Nasdaq ,Green Room Communications ,Eyepoint Pharmaceuticals ,Eyepoint Pharmaceuticals Inc ,Month Safety ,Efficacy Data ,Trial Evaluating ,Hospital Outpatient Rule ,Point Pharmaceuticals ,Investor Day ,Nancy Lurker ,Chief Executive Officer ,American Society ,Retinal Surgeons ,Annual Meeting ,Retina Consultants ,Day Highlights ,Chief Operating Officer ,Chief Technology Officer ,Chief Medical Officer ,Chief Financial Officer ,Hospital Outpatient ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Nasdaq Eypt ,Nc ,